PDT Partners’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

PDT Partners’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-18,800	Closed	-$88K	–	904
2020 Q3	$88K	Sell	18,800 -19,950	-51%	-$101K	0.01%	682
2020 Q2	$236K	Sell	38,750 -30,350	-44%	-$125K	0.02%	571
2020 Q1	$157K	Hold	69,100	–	–	0.01%	584
2019 Q4	$317K	Sell	69,100 -19,200	-22%	-$76K	0.02%	525
2019 Q3	$342K	Buy	+88,300	New	+$485K	0.02%	367
2015 Q3	–	Sell	-33,700	Closed	-$837K	–	1687
2015 Q2	$837K	Buy	+33,700	New	+$751K	0.02%	797

Other funds holding FPRX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PDT Partners's FPRX Position: Q4 2020 in Review

PDT Partners sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2020, closing a stake of 18,800 shares — an estimated $88K sold.

PDT Partners first reported a position in FPRX in Q2 2015 and held it in 6 quarters. The position peaked at $837K in Q2 2015. 125 funds tracked by Wall St. Rank hold FPRX as of Q4 2020.

PDT Partners reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
PDT Partners sold 18,800 Five Prime Therapeutics, Inc. shares in Q4 2020, an estimated $88K.
PDT Partners first reported a position in Five Prime Therapeutics, Inc. in Q2 2015 and held it in 6 quarters.
PDT Partners's Five Prime Therapeutics, Inc. position peaked at $837K in Q2 2015.
125 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2020.

Based on PDT Partners's 13F filing for Q4 2020, filed 16 Feb 2021.